Navigation Links
Questcor Pharmaceuticals Responds to Questions From Investor Blog
Date:1/16/2012

n patients who might be candidates for being treated with Acthar."

5. How much did Questcor originally pay for the rights to Acthar?

Questcor Response:  Questcor rescued Acthar in 2001 after it was abandoned by a large, internationally recognized pharmaceutical company. This other company notified the FDA of their plans to discontinue the manufacture of Acthar due in great measure to the difficulty and expense of the manufacturing and production process. Questcor stepped in and purchased all worldwide rights to Acthar for a nominal price and for a continuing royalty on future net sales. In addition to the purchase price paid at the closing of the transaction, and as was expected at the time of the purchase, Questcor has invested millions of dollars in transferring and improving the manufacturing process, which was necessary in order to continue production and sale of Acthar.

6. How much does Questcor charge for a vial of the drug today?

Questcor Response:  Questcor sells Acthar to its distributor for approximately $27,000 per vial.  The Company is committed to providing access to Acthar to patients who need it, through our support of the Acthar patient assistance programs administered by the National Organization of Rare Disorders as well as by providing Acthar free-of-charge to Childrens' Hospitals throughout the US. Through our support, these and other important patient-oriented support programs have now provided Acthar with a commercial value of over $124 million at no charge to patients since September 2007.

7. Can analysts/investors utilize the popular IMS database to track Acthar prescription trends? If not, when did this change and why?

Questcor Response:  The IMS database service is one of several third-party services that track some pharmaceutical prescription trends.  Questcor is not responsible for the accuracy of the information provided by any of these servic
'/>"/>

SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine technology :

1. Questcor Pharmaceuticals Issues Statement
2. Questcor Pharmaceuticals Reports Strong Finish to 2011
3. Questcor Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference on November 30, 2011
4. Questcor Pharmaceuticals to Present at CLSAs 4th Annual AsiaUSA Forum on November 7, 2011
5. Questcor and Child Neurology Foundation Support the 3rd Annual Infantile Spasms (IS) Awareness Week
6. Questcor Reports Third Quarter Financial Results
7. Questcor to Report Third Quarter 2011 Earnings and Conduct Conference Call on October 25, 2011
8. Questcor Pharmaceuticals Announces Preliminary Operating Metrics for Third Quarter 2011
9. Questcor Pharmaceuticals to Present at the Jefferies Global Healthcare Conference on September 28, 2011
10. Questcor Provides Updated New Paid Prescription Trends
11. UPDATING and ADDING: Questcor Pharmaceuticals to Present at Upcoming Investor Conferences in September
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... Physician E-sampling is becoming well established across ... key marketing sales tactic in recent years. However, some ... a supplement to traditional sampling. According ... E-sampling has been seeded across multiple therapeutic areas- including ... has been in place for five or more years ...
(Date:9/4/2015)... 2015  Janssen Research & Development, LLC (Janssen) ... (FDA) has accepted for Priority Review the Biologics ... for patients with multiple myeloma who are refractory ... immunomodulatory agent (IMiD), or who have received three ... PI and an IMiD. This is referred to ...
(Date:9/4/2015)... , Sept. 4, 2015 Fair Rate Funding, ... Jersey , reports a dramatic increase in lawsuit filings ... of filed Xarelto lawsuits in the Philadelphia ... to over 300 cases.  In the Louisiana ... for the Eastern District of Louisiana , ...
Breaking Medicine Technology:Current and Future Trends in Physician E-Sampling Programs for the Pharmaceutical Industry 2U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma 2U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma 3U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma 4U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma 5U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma 6U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma 7Xarelto Lawsuit Funding Firm, Fair Rate Funding Reports a Steady Rise in Xarelto Product Liability Lawsuit Filings 2Xarelto Lawsuit Funding Firm, Fair Rate Funding Reports a Steady Rise in Xarelto Product Liability Lawsuit Filings 3
... Safety and Pharmacokinetic Results in Healthy Volunteers to be Presented at ... ... (Nasdaq: ANDS ) announced today preliminary results of a Phase I,clinical trial ... trial of ANA598 in patients chronically infected,with hepatitis C virus (HCV). In the ...
... Rehovot, Israel, reported today results of its internal,clinical trial of ... cancer., In the trial a total of 76 sputum ... Healthy individuals that never smoked 2. Heavy smokers with ... cancer patients (Stage 1) 4. Advanced stage lung cancer ...
Cached Medicine Technology:Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients 2Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients 3Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients 4Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients 5Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients 6BioView Reports Interim Results of Early Detection Lung Cancer Diagnostic Test 2
(Date:9/4/2015)... ... September 04, 2015 , ... Keeping mold top of ... the home is quite common. Mold can grow anywhere - on carpet, clothing, food, ... Checking for excessive moisture and water in the home is key to preventing mold ...
(Date:9/4/2015)... (PRWEB) , ... September 04, 2015 , ... “Getting away ... ways for couples to explore, revitalize and strengthen their ‘couple-ness,’” says Jean Claude ... team at Four Seasons Resort Maui, the island’s only Forbes Five Star resort and ...
(Date:9/4/2015)... ... September 04, 2015 , ... Many consumers are looking for a quick and convenient way to ... The patent-pending K Med Cups provide a quick and simple way to brew a hot ... flu or cough. As a result, they enhance comfort and health. The invention features a ...
(Date:9/4/2015)... ... September 04, 2015 , ... The USC Eye Institute is ... 9 nationwide by Doximity. Faculty, residents and staff are honored to have contributed ... the quality of our ophthalmology residency program. Our faculty places a high priority on ...
(Date:9/4/2015)... ... ... access to a doctor can sometimes be a challenge for a variety of reasons. ... affects hospitals’ abilities to provide quality service to those with serious needs, increases insurance ... has recently presented itself, the new telemedicine platform and app, DocChat . ...
Breaking Medicine News(10 mins):Health News:September is Mold Awareness Month 2Health News:September is Mold Awareness Month 3Health News:September is Mold Awareness Month 4Health News:Couples Season at Four Seasons Resort Maui Begins This Week With Best Hotel Rates of the Year through November 2Health News:Couples Season at Four Seasons Resort Maui Begins This Week With Best Hotel Rates of the Year through November 3Health News:Redesigned Packaging for Powdered Medicinal Mix Invented by InventHelp® Client (CBA-2637) 2Health News:USC Ophthalmology Residency Program Ranked in Top 10 by Doximity 2Health News:USC Ophthalmology Residency Program Ranked in Top 10 by Doximity 3Health News:Telemedicine Platform DocChat Announces Launch Offering a Way for Patients to Consult Doctors and Receive Prescriptions 24/7 2Health News:Telemedicine Platform DocChat Announces Launch Offering a Way for Patients to Consult Doctors and Receive Prescriptions 24/7 3
... ... , ... 1, 2010 -- Fenway Bark today announced operational changes to its pet hotel and daycare ... Board of Appeal, to request an Interim Planning Overlay District (“IPOD”) permit to operate its ...
... ... ... ... ...
... ... , ... , , , ... CHARLOTTE, N.C. , ...
... Researchers from Mount Sinai School of Medicine have found ... implantable cardioverter defibrillator (ICD) are rarely having their ICDs ... near the end of life. This first-of-its-kind study of ... 2, 2010 issue of the Annals of Internal ...
... 1, 2010) Robotic surgical technology with its ... touch, even as they operate from a remote ... intersensory integration, and reports that surgical outcomes for ... compare favorably with traditional invasive surgery. Led by ...
... early intervention can help , MONDAY, March 1 (HealthDay ... between depression and obesity, say researchers who reviewed the ... , "We found bidirectional associations between depression and obesity: ... developing depression over time, whereas depressed persons had a ...
Cached Medicine News:Health News:Dog Owners and Southie Residents Welcome Fenway Bark Into the Pack 2Health News:Dog Owners and Southie Residents Welcome Fenway Bark Into the Pack 3Health News:AMA: Physicians Outraged at Today's Steep Medicare Cut 2Health News:AMA: Physicians Outraged at Today's Steep Medicare Cut 3Health News:AMA: Physicians Outraged at Today's Steep Medicare Cut 4Health News:AMA: Physicians Outraged at Today's Steep Medicare Cut 5Health News:AMA: Physicians Outraged at Today's Steep Medicare Cut 6Health News:AMA: Physicians Outraged at Today's Steep Medicare Cut 7Health News:MedCath Corporation Announces Decision to Consider Strategic Options 2Health News:Hospices not deactivating defibrillators in patients 2Health News:Prostate cancer surgeons 'feel' with their eyes 2Health News:Prostate cancer surgeons 'feel' with their eyes 3Health News:Obesity and Depression: A Vicious Circle? 2
... SST™ Tubes contain spray-coated ... gel for serum separation. ... serum determinations in chemistry. ... efficient means of serum ...
MONOJECT Red/Yellow Mottled Stopper...
BD Vacutainer® PST™ Tubes contain spray-coated lithium heparin and a gel for plasma separation. They are used for plasma determinations in chemistry....
Inquire...
Medicine Products: